Strem and Codexis Sign Enzyme Distribution Agreement
News Feb 20, 2013
These enzymes enable efficient conversion of ketones to chiral alcohols or amines.
The screening kits contain enzymes evolved with proprietary CodeEvolver® directed evolution technology. The resulting enzymes are designed to work at industrial process conditions while reducing cost and waste. They will be available through Strem’s overnight delivery service so that researchers are able to quickly screen a small number of diverse biocatalysts to pick the best solution.
“We are pleased to announce this partnership with Strem, a company very well established in the distribution of catalysts to a wide customer base,” said Dr. Peter Seufer-Wasserthal, Senior Vice President, Pharmaceuticals at Codexis. “Based on Strem’s proven network, we are looking forward to giving more customers the opportunity to use industrial enzymes at R&D scale.”
“Strem is pleased to be working with a proven market leader in the field of Biocatalysis,” said Ephraim Honig, Chief Operating Officer at Strem. “The addition of these screening kits broadens the range of synthesis tools we offer our customers and acknowledges the increasingly important role this technology plays in drug discovery and development.”
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE